Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.4186
Abstract: Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new‐generation TKI (NG‐TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population? read more here.
Keywords: second third; general population; generation; third generation ... See more keywords
New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases
Sign Up to like & getrecommendations! Published in 2021 at "Acta Neurochirurgica"
DOI: 10.1007/s00701-021-05043-3
Abstract: New-generation tyrosine kinase inhibitors (TKIs), nilotinib and ponatinib, for chronic myelogenous leukemia (CML) have been reported to cause symptomatic cerebral ischemia. Herein, we report two patients with asymptomatic cerebral artery stenosis associated with these TKIs,… read more here.
Keywords: new generation; cerebrovascular stenosis; generation; tyrosine kinase ... See more keywords